Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by QuantumLeap Healthcare Collaborative
Information provided by (Responsible Party):
QuantumLeap Healthcare Collaborative Identifier:
First received: December 31, 2009
Last updated: July 11, 2016
Last verified: June 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)

Publications automatically indexed to this study by Identifier (NCT Number):